SHIKARI® Q-REMS

Enzyme immunoassay for the quantitative determination of free Infliximab (Remsima®) in serum and plasma

Remsima®,the world first biosimilar mAb (approved in 2013 by EMA). The Agencys Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade®.
The Matriks Biotek Shikari® Infliximab-Remsima® ELISA has been especially developed for the quantitative analysis of free infliximab in serum and plasma samples.

SHIKARI® S-AIR

Enzyme immunoassay for the quantitative determination of antibodies to infliximab Remsima® in serum and plasma.

Remsima®, the world first biosimilar mAb (approved in 2013 by EMA). The Agencys Committee for Medicinal Products for Human Use(CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade.
Infliximab (Remsima®) was associated to the development of anti- Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remsima®. This might lead to severe complications. The Matriks Biotek Shikari®Antibody to Infliximab®ELISA Kit can be efficiently used for monitoring anti- Infliximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti- Infliximab antibodies.

Enzyme immunoassay for the semi-quantitative determination (screening) of total antibodies to infliximab biosimilar (Remsima®) in serum and plasma

Remsima®, the world first biosimilar mAb (approved in 2013 by EMA). In this context, demonstration of anti-infliximab antibodies during treatment with infliximab
(Remsima®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment
regimens. With the Matriks Biotek S-AIR-T ELISA Kit infiliximab-specific antibodies that are bound to infiliximab in serum and can not be detected by free antibody detection kits can
be determined in patients receiving Remsima®.